Syncvault SVTS in Transfidelity FIDEL tauschen

SyncVault, a trailblazing Social Token platform, that has generated $5.6M+ revenue, garnered 22BN views, and processes 140M+ daily micro-transactions. Active across YouTube, Instagram, TikTok, and YouTube Shorts, SyncVault enables influencers, artists, and brands to tokenize fan engagement. Token holders of $SVTS will gain exclusive content access, participate in streaming and promotions, vote on POA, and unlock passive/ active earning opportunities. The platform's token-gated channels foster direct creator-supporter interaction. SyncVault distinguishes itself by ensuring creators receive a higher revenue percentage compared to traditional platforms. Recognized as a Top 100 Global Media Start-Up, SyncVault is reshaping multi-platform social media promotion and monetization.

Neurodegenerative diseases such as Alzheimer's Disease are devastating conditions that impact millions globally. These diseases are driven by the misfolding and aggregation of proteins, which lead to brain cell death and cognitive decline. To make matters worse, as we age our cells become more error-prone, resulting in more errors during protein printing, causing proteins to clump together and form aggregates. Project Transfidelity aims to solve this by improving the accuracy of protein printing, preventing toxic aggregates from forming. Led by Dr. Dimitri Scherbakov and Dr. Rashid Akbergenov, with over 50 years of combined experience in the lab, we have identified two molecules that may improve the efficiency of protein production, potentially preventing protein aggregates, hypothesized to cause dementia. Despite the significant research funding allocated to neurodegenerative diseases, current therapies continue to treat the symptoms caused by the protein aggregates, with little progress made to stop or reverse disease. We’re trying to go after a potential root cause - rather than trying to clear aggregates once they are there, we aim to prevent them from forming in the first place by reducing the production of faulty proteins. With a clear path towards developing novel intellectual property (IP) and an ever-growing target market, we believe we are poised to make an impact on neurodegenerative disorders and the way we age.